Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Announcing the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health ...

The U.S. government targets 15 high-cost medications for Medicare price negotiations for 2027, under the Inflation Reduction ...

Popular weight loss drugs like Ozempic and Wegovy have been added to Medicare's list of medications that will be negotiated ...

Raising the dose of Novo Nordisk A/S’s obesity drug Wegovy helped patients shed more pounds in a trial while still falling ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

Danish pharmaceutical leader Novo Nordisk(NYSE: NVO) is the brains behind Ozempic, as well as sibling GLP-1 medications including Wegovy, Rybelsus, and Saxenda. You'd think with such a robust ...

According to leading data and analytics company GlobalData, Eli Lilly’s Zepbound (tirzepatide) is poised to surpass Novo Nordisk’s Wegovy (semaglutide), despite expectations for continued ...

Eli Lilly's Mounjaro has patients achieving up to 21% weight loss in the SURMOUNT-1 trial, which is significantly higher than the 15% that Novo Nordisk's Wegovy has achieved in comparable trials.